secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orthofix Medical Inc. (OFIX)
CIK:        0000884624
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000950170-25-026062
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orthofix reports record Q4 net sales of $215.7M (+8% YoY); guides FY25 sales $818-826M, adj. EBITDA $82-86M
--------------------------------------------------------------------------------

- Q4 net sales $215.7M (+8% YoY); record BGT $63.9M (+9%) and Global Orthopedics $35.8M (+18% cc).
- Q4 net loss $(29.1)M ($(0.75)/share); adjusted EBITDA $23.9M (11.1% margin) vs $19.6M (9.8%) in Q4 2023.
- FY24 net sales $799.5M (+7%); net loss $(126.0)M vs $(151.4)M; adjusted EBITDA $67.4M (8.4% margin) vs $46.3M.
- Discontinuing M6 artificial disc lines ($23.4M 2024 sales); guides FY25 sales $818-826M (ex-M6, +6.5% cc) and adj. EBITDA $82-86M.
- Long-term CAGR target raised to 6.5-7.5%; Q4 free cash flow $15.2M; cash $85.7M at year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/884624/000095017025026062/0000950170-25-026062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/884624/000095017025026062/ofix-20250225.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-026062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer